Barry A Ginsberg

US Patent:

7404796, Jul 29, 2008

Filed:

Mar 1, 2004

Appl. No.:

10/788475

Inventors:

Barry H. Ginsberg - Wyckoff NJ, US

Assignee:

Becton Dickinson and Company - Franklin Lakes NJ

International Classification:

A61B 5/00
A61B 5/05
A61M 31/00

US Classification:

600365, 600300, 604 65, 604 66

Abstract:

An apparatus and method are provided for determining a patient's carbohydrate to insulin ratio (CIR) and insulin sensitivity factor (ISF), and using these values, along with values for current blood glucose level and deviation from target blood glucose level, for determining insulin dose in view of carbohydrate intake during a particular time period. The apparatus and method employ algorithms that can be implemented in any of a personal computer, personal data assistant, hand held computing device, blood glucose monitor, infusion pump, medication delivery pen, meter, calculator, among other therapeutic, diagnostic or informational devices used for managing a patient's blood glucose levels.

US Patent:

7570980, Aug 4, 2009

Filed:

Sep 10, 2003

Appl. No.:

10/658209

Inventors:

Barry H. Ginsberg - Wyckoff NJ, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

A61B 5/00

US Classification:

600347, 600365

Abstract:

A method of presenting glucose data to a person with diabetes from a blood glucose meter is provided in which an effective meal average (EMA) value is presented, followed by two or more of the individual values that make up the EMA, to provide improved feedback data for clinical decisions by patients who need to alter their dose of insulin. The EMA can also comprise a measure of the variability of its constituent values. The EMA encompasses those values that occur at specified times such as 1 hour before and 1 hour after a specified meal time. The EMA is calculated over a limited number of days previous to the calculation (e. g. , 3 days) and has a minimum number of values that must be obtained within the time and date ranges. An algorithm allows for exclusion of any given reading from the average (e. g. , post-prandial or control solution readings).

US Patent:

8246540, Aug 21, 2012

Filed:

Jul 1, 2008

Appl. No.:

12/216231

Inventors:

Barry H. Ginsberg - Wyckoff NJ, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

A61M 31/00
A61B 5/05

US Classification:

600365, 604 66

Abstract:

An apparatus and method are provided for determining a patient's carbohydrate to insulin ratio (CIR) and insulin sensitivity factor (ISF), and using these values, along with values for current blood glucose level and deviation from target blood glucose level, for determining insulin dose in view of carbohydrate intake during a particular time period. The apparatus and method employ algorithms that can be implemented in any of a personal computer, personal data assistant, hand held computing device, blood glucose monitor, infusion pump, medication delivery pen, meter, calculator, among other therapeutic, diagnostic or informational devices used for managing a patient's blood glucose levels.

US Patent:

20090240129, Sep 24, 2009

Filed:

Jun 3, 2009

Appl. No.:

12/457185

Inventors:

Barry H. Ginsberg - Wyckoff NJ, US

International Classification:

A61B 5/145

US Classification:

600365

Abstract:

A method of presenting glucose data to a person with diabetes from a blood glucose meter is provided in which an effective meal average (EMA) value is presented, followed by two or more of the individual values that make up the EMA, to provide improved feedback data for clinical decisions by patients who need to alter their dose of insulin. The EMA can also comprise a measure of the variability of its constituent values. The EMA encompasses those values that occur at specified times such as 1 hour before and 1 hour after a specified meal time. The EMA is calculated over a limited number of days previous to the calculation (e.g., 3 days) and has a minimum number of values that must be obtained within the time and date ranges. An algorithm allows for exclusion of any given reading from the average (e.g., post-prandial or control solution readings). Patients can use 1 to 8 EMA on any given date range (e.g., preferably 4, that is, breakfast, lunch, supper and bedtime snack).

US Patent:

20190255250, Aug 22, 2019

Filed:

May 7, 2019

Appl. No.:

16/405037

Inventors:

- Franklin Lakes NJ, US
Robert Banik - Edgewater NJ, US
Barry Ginsberg - Wyckoff NJ, US

Assignee:

Becton, Dickinson and Company - Franklin Lakes NJ

International Classification:

A61M 5/142
F04C 14/20
A61M 5/155
F04C 2/08
F04C 2/14

Abstract:

A high pressure delivery system for delivering a medicament, comprising a first chamber for storing a supply of the medicament, a gear pump assembly in fluid communication with the first chamber, said gear pump assembly having a dose inlet and a dose discharge, said dose inlet having a larger diameter than said dose discharge to provide a high pressure discharge, and a fluid connection path in fluid communication with the gear pump assembly for delivering the medicament to a high pressure area.

US Patent:

20160249865, Sep 1, 2016

Filed:

May 9, 2016

Appl. No.:

15/149942

Inventors:

- Franklin Lakes NJ, US
Barry H. GINSBERG - Wyckoff NJ, US

International Classification:

A61B 5/00
G06F 19/00
A61B 5/145

Abstract:

An effective meal average (EMA) value is presented, followed by two or more of the individual values that make up the EMA, to provide improved feedback data for clinical decisions by patients who need to alter their dose of insulin. The EMA can comprise a measure of the variability of its constituent values, encompass values that occur at specified times such as 1 hour before and after a specified meal time, and be calculated over a limited number of days previous to the calculation (e.g., 3 days) and have a minimum number of values that must be obtained within the time and date ranges. An algorithm can exclude any given reading from the average (e.g., post-prandial or control solution readings). Patients can use 1 to 8 EMA on any given date range (e.g., preferably 4, that is, breakfast, lunch, supper and bedtime snack).

US Patent:

20160066865, Mar 10, 2016

Filed:

Nov 18, 2015

Appl. No.:

14/944786

Inventors:

- Franklin Lakes NJ, US
Barry H. GINSBERG - Wyckoff NJ, US

International Classification:

A61B 5/00
G06F 19/00
A61B 5/145

Abstract:

An effective meal average (EMA) value is presented, followed by two or more of the individual values that make up the EMA, to provide improved feedback data for clinical decisions by patients who need to alter their dose of insulin. The EMA can comprise a measure of the variability of its constituent values, encompass values that occur at specified times such as 1 hour before and after a specified meal time, and be calculated over a limited number of days previous to the calculation (e.g., 3 days) and have a minimum number of values that must be obtained within the time and date ranges. An algorithm can exclude any given reading from the average (e.g., post-prandial or control solution readings). Patients can use 1 to 8 EMA on any given date range (e.g., preferably 4, that is, breakfast, lunch, supper and bedtime snack).

US Patent:

20150057612, Feb 26, 2015

Filed:

Sep 5, 2014

Appl. No.:

14/478837

Inventors:

- Franklin Lakes NJ, US
Robert Banik - Edgewater NJ, US
Barry Ginsberg - Wyckoff NJ, US

Assignee:

BECTON, DICKINSON AND COMPANY - Franklin Lakes NJ

International Classification:

A61M 5/142
A61M 5/155

US Classification:

604131

Abstract:

A high pressure delivery device for delivering a medicament includes a first chamber for storing a supply of the medicament and a second chamber in fluid communication with the first chamber. A fluid connection path is in fluid communication with the second chamber for administering the medicament. A valving system is in fluid communication with the first chamber, the second chamber and the fluid connection path. The valving system allows a dose of the medicament to be injected from the first chamber into the second chamber while substantially preventing backflow of the dose into the first chamber and substantially preventing leakage through the fluid connection path. The valving system also allows the dose in the second chamber to be administered through the fluid connection path while substantially preventing the dose from flowing back into the first chamber.